How Will Emerging Treatments for PD-1–Refractory Melanoma Shape the Delivery of Care?

Key Points:

Several recently approved or emerging therapies are poised to impact the treatment landscape for PD-1–refractory melanoma, including tumor-infiltrating lymphocyte (TIL) therapy, T-cell receptor–engineered T-cell (TCR-T) therapies, and novel oncolytic viruses.
These therapies carry the promise of extending overall survival (OS) in patients who have not responded to standard therapies.
However, the increasing logistical complexity and multidisciplinary involvement of these therapies are likely to shape the pattern of how and where they are given.

You must be logged in to post a comment.